Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis

Fcγ receptors as regulators of immune responses

Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947 · see citing works

A quantitative analysis of kinase inhibitor selectivity

Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466 · see citing works

A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D. Y., Hassell, A. M., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K. E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,125 · see citing works

Rational design of inhibitors that bind to inactive kinase conformations

Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,096 · see citing works

Roles of Fc receptors in autoimmunity

Takai, T. (2002) · Nature reviews. Immunology · doi:10.1038/nri856 · Cited by 627 · see citing works

Crystal Structure of Hck in Complex with a Src Family–Selective Tyrosine Kinase Inhibitor

Schindler, T. H., Sicheri, F., Pico, A. R., Gazit, A., Levitzki, A., & Kuriyan, J. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80357-3 · Cited by 429 · see citing works

Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis

Nell, V. P. K., Machold, K. P., Stamm, T. A., Eberl, G., Heinzl, H., Uffmann, M., Smolen, J. S., & Steiner, G. E. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.035691 · Cited by 354 · see citing works

B‐lymphocyte contributions to human autoimmune disease

Yanaba, K., Bouaziz, J., Matsushita, T., MAGRO, C. M. J., Clair, E. W. S., & Tedder, T. F. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00646.x · Cited by 327 · see citing works

Tyrosine Kinases Btk and Tec Regulate Osteoclast Differentiation by Linking RANK and ITAM Signals

Shinohara, M., Koga, T., Okamoto, K., Sakaguchi, S., Arai, K., Yasuda, H., Takai, T., Kodama, T., Morio, T., Geha, R. S., et al. (2008) · Cell · doi:10.1016/j.cell.2007.12.037 · Cited by 321 · see citing works

Therapeutic B cell depletion impairs adaptive and autoreactive CD4 + T cell activation in mice

Bouaziz, J., Yanaba, K., Venturi, G. M., Wang, Y., Tisch, R., Poe, J. C., & Tedder, T. F. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709205105 · Cited by 315 · see citing works

Induction of macrophage secretion of tumor necrosis factor α through Fcγ receptor IIa engagement by rheumatoid arthritis–specific autoantibodies to citrullinated proteins complexed with fibrinogen

Clavel, C., Nogueira, L., Laurent, L., Iobagiu, C., Vincent, C., Sebbag, M., & Serre, G. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23284 · Cited by 278 · see citing works

Chemical Genetics: Where Genetics and Pharmacology Meet

Knight, Z. A., & Shokat, K. M. (2007) · Cell · doi:10.1016/j.cell.2007.01.021 · Cited by 244 · see citing works

The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases

Hamilton, J. A., & Tak, P. P. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24505 · Cited by 217 · see citing works

The Importance of IL-1β and TNF-α, and the Noninvolvement of IL-6, in the Development of Monoclonal Antibody-Induced Arthritis

Kagari, T., Doi, H., & Shimozato, T. (2002) · Journal of Immunology · doi:10.4049/jimmunol.169.3.1459 · Cited by 212 · see citing works

The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective

Satterthwaite, A. B., & Witte, O. N. (2000) · Immunological Reviews · doi:10.1111/j.1600-065x.2000.imr017504.x · Cited by 209 · see citing works

Bruton’s Tyrosine Kinase Is Required for TLR2 and TLR4-Induced TNF, but Not IL-6, Production

Horwood, N. J., Page, T. H., McDaid, J., Palmer, C. D., Campbell, J., Mahon, T., Brennan, F. M., Webster, D., & Foxwell, B. M. J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.6.3635 · Cited by 203 · see citing works

Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling

Lindvall, J. M., Blomberg, K. E. M., Väliaho, J., Vargas, L., Heinonen, J. E., Berglöf, A., Mohamed, A. J., Nore, B. F., Vihinen, M., & Smith, C. I. E. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00225.x · Cited by 199 · see citing works

The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective

Satterthwaite, A. B., & Witte, O. N. (2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.017504.x · Cited by 197 · see citing works

Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig.

Knoerzer, D. B., Karr, R. W., Schwartz, B. D., & Mengle-Gaw, L. J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118146 · Cited by 161 · see citing works

Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases

Marcotte, D. J., Liu, Y., Arduini, R. M., Hession, C. A., Miatkowski, K., Wildes, C. P., Cullen, P. F., Hong, V. S., Hopkins, B. T., Mertsching, E., et al. (2010) · Protein Science · doi:10.1002/pro.321 · Cited by 158 · see citing works

Regulation of B Lymphocyte Development and Activation by Bruton's Tyrosine Kinase

Khan, W. N. (2001) · Immunologic Research · doi:10.1385/ir:23:2-3:147 · Cited by 156 · see citing works

Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease progression

Cook, A. D., Rowley, M. J., Mackay, I. R., Gough, A., & Emery, P. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391015 · Cited by 149 · see citing works

B Cell Depletion Delays Collagen-Induced Arthritis in Mice: Arthritis Induction Requires Synergy between Humoral and Cell-Mediated Immunity

Yanaba, K., Hamaguchi, Y., Venturi, G. M., Steeber, D. A., Clair, E. W. S., & Tedder, T. F. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.1369 · Cited by 145 · see citing works

Regulation of B‐cell activation and differentiation by the phosphatidylinositol 3‐kinase and phospholipase Cγ pathways

(2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.00611.x · Cited by 138 · see citing works

Four Tyrosine Residues in Phospholipase C-γ2, Identified as Btk-dependent Phosphorylation Sites, Are Required for B Cell Antigen Receptor-coupled Calcium Signaling

Watanabe, D., Hashimoto, S., Ishiai, M., Matsushita, M., Baba, Y., Kishimoto, T., Kurosaki, T., & Tsukada, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103675200 · Cited by 136 · see citing works

A crucial role for macrophages in the pathology of K/B × N serum‐induced arthritis

Solomon, S., Rajasekaran, N., Jeisy‐Walder, E., Snapper, S. B., & Illges, H. (2005) · European Journal of Immunology · doi:10.1002/eji.200526167 · Cited by 135 · see citing works

Dual Functions of Bruton’s Tyrosine Kinase and Tec Kinase during Fcγ Receptor-Induced Signaling and Phagocytosis

Jongstra‐Bilen, J., Cano, A. P., Hasija, M., Xiao, H., Smith, C. I. E., & Cybulsky, M. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.288 · Cited by 132 · see citing works

Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses

Mangla, A. G., Khare, A., Varanasi, V., Panday, N. N., Mukhopadhyay, A., Ravindran, B., Bal, V., George, A., & Rath, S. (2004) · Blood · doi:10.1182/blood-2004-01-0207 · Cited by 128 · see citing works

Btk Regulates B Cell Receptor-Mediated Antigen Processing and Presentation by Controlling Actin Cytoskeleton Dynamics in B Cells

Sharma, S., Orlowski, G. M., & Song, W. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.329 · Cited by 126 · see citing works

Mechanism of B-Cell Receptor-Induced Phosphorylation and Activation of Phospholipase C-γ2

Kim, Y. J., Sekiya, F., Poulin, B., Bae, Y. S., & Rhee, S. G. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.22.9986-9999.2004 · Cited by 126 · see citing works

The role of antibodies in mouse models of rheumatoid arthritis, and relevance to human disease.

Monach, P., Benoist, C., & Mathis, D. (2004) · Advances in Immunology · doi:10.1016/s0065-2776(04)82005-4 · Cited by 118 · see citing works

Essential Role of Fcγ Receptors in Anti-Type II Collagen Antibody-Induced Arthritis

Kagari, T., Tanaka, D., Doi, H., & Shimozato, T. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.8.4318 · Cited by 114 · see citing works

Role of Bruton's tyrosine kinase in immunodeficiency

Tsukada, S., Rawlings, D. J., & Witte, O. N. (1994) · Current Opinion in Immunology · doi:10.1016/0952-7915(94)90151-1 · Cited by 112 · see citing works

The Tec Family Tyrosine Kinase Btk Regulates RANKL-induced Osteoclast Maturation

Lee, S. H., Kim, T. S., Jeong, D., Kim, N., & Choi, Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708935200 · Cited by 106 · see citing works

Tec Kinases Mediate Sustained Calcium Influx via Site-specific Tyrosine Phosphorylation of the Phospholipase Cγ Src Homology 2-Src Homology 3 Linker

Humphries, L. A., Dangelmaier, C., Sommer, K., Kipp, K. R., Kato, R. M., Griffith, N., Bakman, I., Turk, C. W., Daniel, J. L., & Rawlings, D. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311985200 · Cited by 103 · see citing works

Bruton's Tyrosine Kinase is involved in innate and adaptive immunity.

Brunner, C., Müller, B., & Wirth, T. C. (2005) · PubMed · doi:10.14670/hh-20.945 · Cited by 102 · see citing works

A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis

Katschke, K. J., Helmy, K. Y., Steffek, M., Xi, H., Yin, J., Lee, W. P., Gribling, P., Barck, K. H., Carano, R. A. D., Taylor, R. E., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070432 · Cited by 100 · see citing works

The Role of Tec Family Kinases in Myeloid Cells

Schmidt, U., Boucheron, N., Unger, B., & Ellmeier, W. (2004) · International Archives of Allergy and Immunology · doi:10.1159/000078339 · Cited by 92 · see citing works

Genes on the X chromosome affect development of collagen-induced arthritis in mice

Jansson, L., & Holmdahl, R. (1993) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1993.tb08218.x · Cited by 85 · see citing works

Autoantibodies to citrullinated proteins: ACPA

Vincent, C., Nogueira, L., Clavel, C., Sebbag, M., & Serre, G. (2005) · Autoimmunity · doi:10.1080/08916930400022582 · Cited by 75 · see citing works

Bmx tyrosine kinase regulates TLR4-induced IL-6 production in human macrophages independently of p38 MAPK and NFκB activity

Palmer, C. D., Mutch, B. E., Workman, S., McDaid, J., Horwood, N. J., & Foxwell, B. M. J. (2007) · Blood · doi:10.1182/blood-2007-07-102343 · Cited by 73 · see citing works

Surface‐bound anti–type II collagen–containing immune complexes induce production of tumor necrosis factor α, interleukin‐1β, and interleukin‐8 from peripheral blood monocytes via fcγ receptor IIA: A potential pathophysiologic mechanism for humoral anti–type II collagen immunity in arthritis

Mullazehi, M., Mathsson, L., Lampa, J., & Rönnelid, J. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21892 · Cited by 73 · see citing works

Contribution of Fcγ receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis

Thabet, M. M., Huizinga, T. W. J., Marques, R. B., Stoeken‐Rijsbergen, G., Bakker, A. M., Kurreeman, F. A. S., White, S. J., Toes, R. E. M., & Mil, A. H. M. V. D. H. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.099309 · Cited by 53 · see citing works

ANTIBODIES TO TYPE II COLLAGEN IN EARLY RHEUMATOID ARTHRITIS

Morgan, K., Clague, R. B., REYNOLDS, I., & Davis, M. R. (1993) · Lara D. Veeken · doi:10.1093/rheumatology/32.4.333 · Cited by 47 · see citing works

Induction of costimulatory molecules B7-1 and B7-2 in murine B cells: The CBAN mouse reveals a role for Bruton's tyrosine kinase in CD40-mediated B7 induction

Goldstein, M. D., Debenedette, M. A., Hollenbaugh, D. L., & Watts, T. H. (1996) · Molecular Immunology · doi:10.1016/0161-5890(96)00005-3 · Cited by 33 · see citing works

Bruton's tyrosine kinase as a drug discovery target

Pan, Z. (2008) · Drug News & Perspectives · doi:10.1358/dnp.2008.21.7.1255308 · Cited by 30 · see citing works

Activation Loop Phosphorylation Modulates Bruton’s Tyrosine Kinase (Btk) Kinase Domain Activity

Lin, L., Czerwiński, R., Kelleher, K. S., Siegel, M. M., Wu, P. W., Kriz, R., AULABAUGH, A. E., & Stahl, M. (2009) · Biochemistry · doi:10.1021/bi8019756 · Cited by 24 · see citing works

The complex role of Fcγ receptors in the pathology of arthritis

Boross, P., & Verbeek, J. S. (2006) · Springer Seminars in Immunopathology · doi:10.1007/s00281-006-0049-9 · Cited by 23 · see citing works

B cell-directed therapy in rheumatoid arthritis--clinical experience.

Panayi, G. S. (2005) · PubMed · Cited by 18 · see citing works

FcγRIII‐Expressing Macrophages are Essential for Development of Collagen‐Induced Arthritis

Andr�en, M., Xiang, Z., Nilsson, G. P., & Kleinau, S. (2006) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2006.01743.x · Cited by 16 · see citing works

Skepinone-L, a Novel Potent and Highly Selective Inhibitor of p38 MAP Kinase, Effectively Impairs Platelet Activation and Thrombus Formation

Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. J. W. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,867 · see citing works

Pathogenetic insights from the treatment of rheumatoid arthritis

McInnes, I. B., & Schett, G. A. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31472-1 · Cited by 1,353 · see citing works

PROTACs: past, present and future

Li, K., & Crews, C. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00193d · Cited by 869 · see citing works

B cell depletion therapies in autoimmune disease: advances and mechanistic insights

Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 666 · see citing works

Targeting Bruton's tyrosine kinase in B cell malignancies

Hendriks, R. W., Yuvaraj, S., & Kil, L. P. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3702 · Cited by 564 · see citing works

Prolonged and tunable residence time using reversible covalent kinase inhibitors

Bradshaw, J. M., McFarland, J. M., Paavilainen, V. O., Bisconte, A. R., Tam, D., Phan, V. T., Romanov, S., Finkle, D., Shu, J., Patel, V. P., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1817 · Cited by 428 · see citing works

Kinase inhibition in autoimmunity and inflammation

Zarrin, A. A., Bao, K., Lupardus, P., & Vucic, D. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0082-8 · Cited by 431 · see citing works

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase

Guo, Y., Liu, Y., Hu, N., Yu, D., Zhou, C., Shi, G., Zhang, B., Wei, M., Liu, J., Luo, L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00687 · Cited by 372 · see citing works

Chemistries of bifunctional PROTAC degraders

Cao, C., He, M., Wang, L., He, Y., & Rao, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00220e · Cited by 313 · see citing works

Drug–Target Kinetics in Drug Discovery

Tonge, P. J. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00185 · Cited by 295 · see citing works

The ins and outs of selective kinase inhibitor development

Müller, S., Chaikuad, A., Gray, N. S., & Knapp, S. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1938 · Cited by 276 · see citing works

Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity

Weber, A. N. R., Bittner, Z., Liu, X., Dang, T., Radsak, M. P., & Brunner, C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01454 · Cited by 271 · see citing works

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Walter, H. S., Rule, S. A., Dyer, M. J. S., Karlin, L., Jones, C. H., Cazin, B., Quittet, P., Shah, N., Hutchinson, C. V., Honda, H., et al. (2015) · Blood · doi:10.1182/blood-2015-08-664086 · Cited by 270 · see citing works

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development

Crawford, J. J., Johnson, A. R., Misner, D., Belmont, L. D., Castanedo, G. M., Choy, R., Coraggio, M., Dong, L., Eigenbrot, C. W., Erickson, R., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01712 · Cited by 263 · see citing works

Ibrutinib and novel BTK inhibitors in clinical development

Akinleye, A., Chen, Y., Mukhi, N., Song, Y., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-59 · Cited by 233 · see citing works

Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans

Evans, E. K., Tester, R. W., Aslanian, S., Karp, R., Sheets, M. P., Labenski, M., Witowski, S. R., Lounsbury, H. A., Chaturvedi, P., Mazdiyasni, H., et al. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203489 · Cited by 223 · see citing works

Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity

Kohrt, H. E. K., Sagiv-Barfi, I., Rafiq, S., Herman, S. E. M., Butchar, J. P., Cheney, C. M., Zhang, X., Buggy, J. J., Muthusamy, N., Levy, R., et al. (2014) · Blood · doi:10.1182/blood-2014-01-547869 · Cited by 218 · see citing works

Bruton tyrosine kinase inhibitors for multiple sclerosis

Krämer, J., Bar-Or, A., Turner, T. J., & Wiendl, H. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00800-7 · Cited by 206 · see citing works

Ability of Bruton’s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling

Bender, A. T., Gardberg, A. S., Pereira, A., Johnson, T. L., Wu, Y., Grenningloh, R., Head, J. C., Morandi, F., Haselmayer, P., & Liu‐Bujalski, L. (2017) · Molecular Pharmacology · doi:10.1124/mol.116.107037 · Cited by 199 · see citing works

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase

Angst, D., Gessier, F., Janser, P., Vulpetti, A., Wälchli, R., Beerli, C., Littlewood-Evans, A. J., Dawson, J., Nuesslein‐Hildesheim, B., Wieczorek, G., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01916 · Cited by 179 · see citing works

The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review

Liang, C., Tian, D., Ren, X., Ding, S., Jia, M., Xin, M., & Thareja, S. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.062 · Cited by 178 · see citing works

Bruton tyrosine kinase degradation as a therapeutic strategy for cancer

Dobrovolsky, D., Wang, E. S., Morrow, S., Leahy, C., Faust, T., Nowak, R. P., Donovan, K. A., Yang, G., Li, Z., Fischer, E. S., et al. (2019) · Blood · doi:10.1182/blood-2018-07-862953 · Cited by 169 · see citing works

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

Tai, Y., Chang, B. Y., Kong, S., Fulciniti, M., Yang, G., Calle, Y., Hu, Y., Lin, J., Zhao, J., Cagnetta, A., et al. (2012) · Blood · doi:10.1182/blood-2011-12-396853 · Cited by 165 · see citing works

BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies

Alu, A., Lei, H., Han, X., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01353-w · Cited by 157 · see citing works

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)

Burger, J. A., & Buggy, J. J. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.777837 · Cited by 156 · see citing works

Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers

Watterson, S. H., Lucca, G. V. D., Shi, Q., Langevine, C. M., Liu, Q., Batt, D. G., Bertrand, M. B., Gong, H., Dai, J., Yip, S. H., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01088 · Cited by 153 · see citing works

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases

Caldwell, R. D., Qiu, H., Askew, B. C., Bender, A. T., Brügger, N., Camps, M., Dhanabal, M., Dutt, V., Eichhorn, T., Gardberg, A. S., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00794 · Cited by 150 · see citing works

Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models

Haselmayer, P., Camps, M., Liu‐Bujalski, L., Nguyen, N. T. K., Morandi, F., Head, J. C., O’Mahony, A., Zimmerli, S. C., Bruns, L., Bender, A. T., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800583 · Cited by 143 · see citing works

The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy

Crofford, L. J., Nyhoff, L. E., Sheehan, J. H., & Kendall, P. L. (2016) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1152888 · Cited by 142 · see citing works

RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents

Xu, D., Kim, Y. D., Postelnek, J., Vu, M. D., Hu, D., Liao, C., Bradshaw, M., Hsu, J., Zhang, J., Pashine, A., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.187740 · Cited by 142 · see citing works

A public-private partnership to unlock the untargeted kinome

Knapp, S., Arruda, P., Blagg, J., Burley, S. K., Drewry, D. H., Edwards, A. M., Fabbro, D., Gillespie, P., Gray, N. S., Küster, B., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1113 · Cited by 139 · see citing works

BTK Signaling in B Cell Differentiation and Autoimmunity

Corneth, O. B. J., Wolterink, R. G. J. K., & Hendriks, R. W. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_478 · Cited by 140 · see citing works

Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations

Johnson, A. R., Kohli, P. B., Katewa, A., Gogol, E., Belmont, L. D., Choy, R., Penuel, E., Burton, L., Eigenbrot, C., Yu, C., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00480 · Cited by 137 · see citing works

Human NACHT, LRR, and PYD domain–containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase

Liu, X., Pichulik, T., Wolz, O., Dang, T., Stutz, A., Dillen, C. A., Garcia, M. D., Kraus, H., Dickhöfer, S., Daiber, E., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.017 · Cited by 132 · see citing works

Applications of organocatalysed visible-light photoredox reactions for medicinal chemistry

Bogdos, M. K., Pinard, E., & Murphy, J. A. (2018) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.14.179 · Cited by 129 · see citing works

Bruton's Tyrosine Kinase: From X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies

Ponader, S., & Burger, J. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1046 · Cited by 123 · see citing works

Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate

Wang, Q., Vogan, E. M., Nocka, L. M., Rosen, C. E., Zorn, J. A., Harrison, S. C., & Kuriyan, J. (2015) · eLife · doi:10.7554/elife.06074 · Cited by 125 · see citing works

Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK)

Watterson, S. H., Liu, Q., Bertrand, M. B., Batt, D. G., Li, L., Pattoli, M. A., Skala, S., Cheng, L., Obermeier, M. T., Moore, R., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00167 · Cited by 120 · see citing works

Phenazinium Salt-Catalyzed Aerobic Oxidative Amidation of Aromatic Aldehydes

Leow, D. (2014) · Organic Letters · doi:10.1021/ol5029354 · Cited by 119 · see citing works

CGI1746 targets σ1R to modulate ferroptosis through mitochondria-associated membranes

Zhang, Z., Zhou, H., Gu, W., Wei, Y., Mou, S., Wang, Y., Zhang, J., & Zhong, Q. (2024) · Nature Chemical Biology · doi:10.1038/s41589-023-01512-1 · Cited by 124 · see citing works

Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis

Rankin, A. L., Seth, N., Keegan, S., Andreyeva, T., Cook, T. A., Edmonds, J., Mathialagan, N., Benson, M. J., Syed, J., Zhan, Y., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301553 · Cited by 113 · see citing works

Structure-Based Drug Design of RN486, a Potent and Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis

Lou, Y. C., Han, X., Kuglstatter, A., Kondru, R. K., Sweeney, Z. K., Soth, M., McIntosh, J. E., Litman, R., Suh, J. M., Koçer, B., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500305p · Cited by 112 · see citing works

A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers

Smith, P. F., Krishnarajah, J., Nunn, P. A., Hill, R. J., Karr, D. E., Tam, D., Masjedizadeh, M. R., Funk, J. O., & Gourlay, S. G. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13351 · Cited by 108 · see citing works

Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease

Corneth, O. B. J., Verstappen, G. M. P. J., Paulissen, S. M. J., de Bruijn, M. J. W., Rip, J., Lukkes, M. M., van Hamburg, J. P., Lubberts, E., Bootsma, H., Kroese, F. G. M., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40059 · Cited by 108 · see citing works

The NLRP3 inflammasome and bruton's tyrosine kinase in platelets co-regulate platelet activation, aggregation, and in vitro thrombus formation

Murthy, P., Durco, F., Miller-Ocuin, J. L., Takedai, T., Shankar, S., Liang, X., Liu, X., Cui, X. D., Sachdev, U., Rath, D., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.161 · Cited by 107 · see citing works

The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia

Qorraj, M., Bruns, H., Böttcher, M., Weigand, L., Saul, D., Mackensen, A., Jitschin, R., & Mougiakakos, D. (2016) · Leukemia · doi:10.1038/leu.2016.214 · Cited by 104 · see citing works

Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials

Burger, J. A. (2013) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-013-0188-8 · Cited by 100 · see citing works

Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases

Xie, Z., Yang, X., Duan, Y., Han, J., & Liao, C. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01511 · Cited by 102 · see citing works

Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease

von Hundelshausen, P., & Siess, W. (2021) · Cancers · doi:10.3390/cancers13051103 · Cited by 100 · see citing works

Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies

Gu, D., Tang, H., Wu, J., Li, J., & Miao, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01049-7 · Cited by 99 · see citing works

Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition

Liclican, A. C., Serafini, L., Xing, W., Czerwieniec, G. A., Steiner, B. H., Wang, T., Brendza, K. M., Lutz, J. D., Keegan, K. S., Ray, A. S., et al. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129531 · Cited by 98 · see citing works

Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus

Hutcheson, J., Vanarsa, K., Bashmakov, A., Grewal, S., Sajitharan, D., Chang, B. Y., Buggy, J. J., Zhou, X. J., Du, Y., Satterthwaite, A. B., et al. (2012) · Arthritis Research & Therapy · doi:10.1186/ar4086 · Cited by 96 · see citing works

Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis

Whang, J. A., & Chang, B. Y. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.028 · Cited by 95 · see citing works

Exploring the target scope of KEAP1 E3 ligase-based PROTACs

Du, G., Jiang, J., Henning, N. J., Safaee, N., Koide, E., Nowak, R. P., Donovan, K. A., Yoon, H., You, I., Yue, H., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.08.003 · Cited by 94 · see citing works

Antiarthritis Effect of a Novel Bruton’s Tyrosine Kinase (BTK) Inhibitor in Rat Collagen-Induced Arthritis and Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling: Relationships between Inhibition of BTK Phosphorylation and Efficacy

Liu, L., Paolo, J. A. D., Barbosa, J., Rong, H., Reif, K., & Wong, H. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.181545 · Cited by 89 · see citing works

Bruton’s Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies

Lou, Y. C., Owens, T. D., Kuglstatter, A., Kondru, R. K., & GOLDSTEIN, D. M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300035p · Cited by 88 · see citing works

Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib

Yu, J., Chen, L., Cui, B., Wu, C. C. N., Choi, M. Y., Chen, Y., Zhang, L., Rassenti, L. Z., Widhopf, G. F., & Kipps, T. J. (2016) · Leukemia · doi:10.1038/leu.2016.368 · Cited by 87 · see citing works

7-Azaindole: A Versatile Scaffold for Developing Kinase Inhibitors

Irie, T., & Sawa, M. (2017) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c17-00380 · Cited by 87 · see citing works

Discovery of a Potent BTK Inhibitor with a Novel Binding Mode by Using Parallel Selections with a DNA‐Encoded Chemical Library

Cuozzo, J. W., Gikunju, D., Habeshian, S., Hupp, C. D., Keefe, A. D., Sigel, E. A., Soutter, H. H., Thomson, H. A., Zhang, Y., & Clark, M. (2017) · ChemBioChem · doi:10.1002/cbic.201600573 · Cited by 81 · see citing works

BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib

Estupiñán, H. Y., Wang, Q., Berglöf, A., Schaafsma, G. C. P., Shi, Y., Zhou, L., Mohammad, D. K., Yu, L., Vihinen, M., Zain, R., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01123-6 · Cited by 80 · see citing works

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies

Neys, S. F. H., Hendriks, R. W., & Corneth, O. B. J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.668131 · Cited by 80 · see citing works

BTK Modulates p53 Activity to Enhance Apoptotic and Senescent Responses

Althubiti, M., Rada, M., Samuel, J., Escorsa, J. M., Najeeb, H., Lee, K.-G., Lam, K., Jones, G. D. D., Barlev, N. A., & Macip, S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0690 · Cited by 76 · see citing works

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma

Wu, H., Wang, W., Liu, F., Weisberg, E., Tian, B., Chen, Y., Li, B., Wang, A., Wang, B., Zhao, Z., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb4008524 · Cited by 76 · see citing works

Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib

Ran, F., Liu, Y., Wang, C., Xu, Z., Zhang, Y., Liu, Y., Zhao, G., & Ling, Y. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114009 · Cited by 74 · see citing works

Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives

Robak, E., & Robak, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102807 · Cited by 75 · see citing works

Bruton Tyrosine Kinase Is a Therapeutic Target in Stem-like Cells from Multiple Myeloma

Yang, Y., Shi, J., Gu, Z., Salama, M. E., Das, S., Wendlandt, E. B., Xu, H., Huang, J., Yi, T., Hao, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2362 · Cited by 75 · see citing works

Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton’s Tyrosine Kinase

Smith, C. R., Dougan, D. R., Komandla, M., Kanouni, T., Knight, B., Lawson, J. D., Sabat, M. P., Taylor, E. R., Vu, P. H., & Wyrick, C. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00734 · Cited by 75 · see citing works

Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton’s Tyrosine Kinase Inhibitor

Liu, L., Halladay, J. S., Shin, Y. G., Wong, S., Coraggio, M., La, H., Baumgardner, M., Le, H. T., Gopaul, S. V., Boggs, J. W., et al. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040840 · Cited by 74 · see citing works

Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases

Zhang, D., He, G., & Meng, F. (2021) · Molecules · doi:10.3390/molecules26164907 · Cited by 74 · see citing works

The Development of BTK Inhibitors: A Five-Year Update

Tasso, B., Spallarossa, A., Russo, E., & Brullo, C. (2021) · Molecules · doi:10.3390/molecules26237411 · Cited by 73 · see citing works

Tec Family Kinases in Inflammation and Disease

Horwood, N. J., Urbaniak, A. M., & Danks, L. (2012) · International Reviews of Immunology · doi:10.3109/08830185.2012.670334 · Cited by 73 · see citing works

Tyrosine Kinase Btk Is Required for NK Cell Activation

Bao, Y., Zheng, J. H., Han, C., Jin, J., Han, H., Liu, Y., Lau, Y., Tu, W., & Cao, X. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.372425 · Cited by 73 · see citing works

Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell–associated damage in IFNα-driven lupus nephritis

Katewa, A., Wang, Y., Hackney, J. A., Huang, T., Suto, E., Ramamoorthi, N., Austin, C. D., Bremer, M. C. D., Chen, J. Z., Crawford, J. J., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.90111 · Cited by 72 · see citing works

Structural mechanism for Bruton’s tyrosine kinase activation at the cell membrane

Wang, Q., Pechersky, Y., Sagawa, S., Pan, A. C., & Shaw, D. E. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819301116 · Cited by 72 · see citing works

Emerging small-molecule inhibitors of the Bruton’s tyrosine kinase (BTK): Current development

Liu, J., Chen, C., Wang, D., Zhang, J., & Zhang, T. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113329 · Cited by 71 · see citing works

BODIPY catalyzed amide synthesis promoted by BHT and air under visible light

Wang, X., Yu, S.-S., Wang, C., Xue, D. Q., & Xiao, J. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob00736h · Cited by 71 · see citing works

B-Cell Receptor Signaling Inhibitors for Treatment of Autoimmune Inflammatory Diseases and B-Cell Malignancies

Puri, K. D., Paolo, J. A. D., & Gold, M. R. (2013) · International Reviews of Immunology · doi:10.3109/08830185.2013.818140 · Cited by 69 · see citing works

Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function

Ren, L., Campbell, A. R., Fang, H., Gautam, S., Elavazhagan, S., Fatehchand, K., Mehta, P., Stiff, A. R., Reader, B. F., Mo, X. M., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.687251 · Cited by 69 · see citing works

Potent and selective Bruton’s tyrosine kinase inhibitors: Discovery of GDC-0834

Young, W. B., Barbosa, J., Blomgren, P., Bremer, M. C. D., Crawford, J. J., Dambach, D. M., Gallion, S., Hymowitz, S. G., Kropf, J. E., Lee, S., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.01.032 · Cited by 68 · see citing works

HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis

Park, J. K., Byun, J., Park, J. A., Kim, Y.-Y., Lee, Y. J., Oh, J. I., Jang, S. Y., Kim, Y., Song, Y. W., Son, J., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0988-z · Cited by 68 · see citing works

Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations

Lu, X., Smaill, J. B., & Ding, K. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00507 · Cited by 67 · see citing works

Targeting the SYK–BTK axis for the treatment of immunological and hematological disorders

Tan, S., Liao, C., Lucas, M. C., Stevenson, C. S., & DeMartino, J. A. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.02.001 · Cited by 64 · see citing works

Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton’s Tyrosine Kinase with in Vivo Antitumor Activity

Li, X., Zuo, Y., Tang, G., Wang, Y., Zhou, Y., Wang, X., Guo, T., Xia, M., Ding, N., & Pan, Z. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4017762 · Cited by 64 · see citing works

Cinnoline Scaffold—A Molecular Heart of Medicinal Chemistry?

Szumilak, M., & Stańczak, A. (2019) · Molecules · doi:10.3390/molecules24122271 · Cited by 63 · see citing works

Bruton’s tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells

Nadeem, A., Ahmad, S. F., Al-Harbi, N. O., El‐Sherbeeny, A. M., Alasmari, A. F., Alanazi, W. A., Alasmari, F. F., Ibrahim, K. E., Al‐Harbi, M. M., Bakheet, S. A., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106215 · Cited by 63 · see citing works

Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis

Kim, K., Maderna, A., Schnute, M. E., Hegen, M., Mohan, S., Miyashiro, J. S., Lin, L., Li, E., Keegan, S., Lussier, J., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.09.008 · Cited by 63 · see citing works

Targeting B cells in treatment of autoimmunity

Franks, S. E., Getahun, A., Hogarth, P. M., & Cambier, J. C. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.09.003 · Cited by 61 · see citing works

Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease

Bam, R., Ling, W., Khan, S., Pennisi, A., Venkateshaiah, S. U., Li, X., van Rhee, F., Usmani, S. Z., Barlogie, B., Shaughnessy, J. D., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23433 · Cited by 61 · see citing works

Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study

Montillo, M., O'Brien, S. M., Tedeschi, A., Byrd, J. C., Dearden, C. E., Gill, D. S., Brown, J. R., Barrientos, J. C., Mulligan, S. P., Furman, R. R., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.5 · Cited by 61 · see citing works

Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells

Al-Harbi, N. O., Nadeem, A., Ahmad, S. F., Bakheet, S. A., El‐Sherbeeny, A. M., Ibrahim, K. E., Alzahrani, K. S., Al‐Harbi, M. M., Mahmood, H. M., Alqahtani, F., et al. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173088 · Cited by 60 · see citing works

Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells

Hasan, M. K., Yu, J., Chen, L., Cui, B., Widhopf, G. F., Rassenti, L. Z., Shen, Z., Briggs, S. P., & Kipps, T. J. (2017) · Leukemia · doi:10.1038/leu.2017.133 · Cited by 60 · see citing works

Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care

Gillooly, K. M., Pulicicchio, C. M., Pattoli, M. A., Cheng, L., Skala, S., Heimrich, E., McIntyre, K. W., Taylor, T. L., Kukral, D. W., Dudhgaonkar, S. P., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181782 · Cited by 59 · see citing works

Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis

Torke, S., & Weber, M. S. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1807934 · Cited by 57 · see citing works

A Fast and Clean BTK Inhibitor

Gabizon, R., & London, N. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00597 · Cited by 56 · see citing works

Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease

Neys, S. F. H., Rip, J., Hendriks, R. W., & Corneth, O. B. J. (2021) · Drugs · doi:10.1007/s40265-021-01592-0 · Cited by 58 · see citing works

Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells

Wang, X., Wong, J., Sevinsky, C. J., Kokabee, L., Khan, F., Sun, Y., & Conklin, D. S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0813 · Cited by 55 · see citing works

Emerging nanotherapeutics alleviating rheumatoid arthritis by readjusting the seeds and soils

Zhang, W., Chen, Y., Liu, Q., Zhou, M. L., Wang, K., Wang, Y., Nie, J., Gui, S., Peng, D., He, Z., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.001 · Cited by 54 · see citing works

New Btk inhibitor holds promise

Hendriks, R. W. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.502 · Cited by 54 · see citing works

Enhanced Expression of Bruton’s Tyrosine Kinase in B Cells Drives Systemic Autoimmunity by Disrupting T Cell Homeostasis

Corneth, O. B. J., de Bruijn, M. J. W., Rip, J., Asmawidjaja, P. S., Kil, L. P., & Hendriks, R. W. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600208 · Cited by 53 · see citing works

Toll-like receptor 4–, 7–, and 8–activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokines

Marron, T. U., Martínez‐Gallo, M., Yu, J. E., & Cunningham‐Rundles, C. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.10.009 · Cited by 52 · see citing works

HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis

Park, J. K., Byun, J., Park, J. A., Kim, Y.-Y., Lee, Y. J., Oh, J. I., Jang, S. Y., Kim, Y., Song, Y. W., Son, J., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0988-z · Cited by 68 · see citing works

Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis

Whang, J. A., & Chang, B. Y. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.028 · Cited by 95 · see citing works

A novel Highly Specific Small Molecule Inhibitor for BTK Suppresses Fc Receptor Function in Macrophages and Prevents Inflammatory Arthritis (96.18)

Reif, K., Huang, T., Barbosa, J., Hymowitz, S. G., Gallion, S. L., Hurez, V. J., Maciejewski, P. M., Dennis, G., Rong, H., Shen, F., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.184.supp.96.18

Therapeutic potential and recent progression of BTK inhibitors against rheumatoid arthritis

Paliwal, S., Bawa, S., Shalmali, N., & Tonk, R. K. (2024) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14582 · Cited by 7 · see citing works

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model

Wu, H., Huang, Q., Qi, Z., Chen, Y., Wang, A., Chen, C., Liang, Q., Wang, J., Chen, W., Dong, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00482-4 · Cited by 23 · see citing works